118
Participants
Start Date
October 30, 2018
Primary Completion Date
November 5, 2021
Study Completion Date
November 5, 2021
Pembrolizumab
Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
Pemetrexed
Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
Carboplatin
Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
Cisplatin
Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
Orszagos Koranyi TBC es Pulmonologiai Intezet ( Site 0400), Budapest
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0401), Szolnok
Petz Aladar Megyei Oktato Korhaz ( Site 0402), Győr
Harry & Jeanette Weinberg Cancer Institute ( Site 0901), Baltimore
Hospital General Universitario 12 de Octubre ( Site 0703), Madrid
Hospital Puerta de Hierro ( Site 0702), Majadahonda
Hospital Universitario Central de Asturias ( Site 0704), Oviedo
Hospital Universitario Insular de Gran Canaria ( Site 0700), Las Palmas de Gran Canaria
Henry Ford Health System ( Site 0903), Detroit
University Of Colorado ( Site 0908), Aurora
Meir Medical Center ( Site 0501), Kfar Saba
Chaim Sheba Medical Center ( Site 0500), Ramat Gan
Kingston General Hospital ( Site 0800), Kingston
CISSS de la Monteregie-Centre ( Site 0801), Greenfield Park
H.U. Vall de Hebron ( Site 0701), Barcelona
Merck Sharp & Dohme LLC
INDUSTRY